New York, Dec 09, 2014 – Merck & Co Inc said on Monday it would buy Cubist Pharmaceuticals Inc in a deal valued at $9.5 billion, giving the major drugmaker an entry into the market for drugs that target so-called superbugs.
Merck and British rival AstraZeneca Plc have turned their attention to newer kinds of antibiotics that attack superbugs — strains of bacteria that are resistant to several types of antibiotics — after the 2013 threat report from the U.S. Centers for Disease Control (CDC) and Prevention.
The CDC estimated that more than two million people in the United States are sickened every year by such infections, with at least 23,000 dying as a result.
Cubist’s lead drug, Ceftolozane/Tazobactamis, is widely expected to win marketing approval from the U.S. Food and Drug Administration later this month as a treatment for complicated urinary tract infections.
The deal includes assumption of $1.1 billion in debt. Business Line
Hyderabad, December 26, 2024: Dr. Narendranadh Meda, one of the city’s leading Vascular, Endovascular &…
Bangalore, December 26, 2024: Bangalore Hospitals, a renowned brand in healthcare innovation and quality, has introduced…
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…